SKYE Stock Summary and Trading Ideas (Skye Bioscience | NASDAQ:SKYE)

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Skye Bioscience trades on the NASDAQ stock market under the symbol SKYE.

As of June 15, 2026, SKYE stock price declined to $0.73 with 180,909 million shares trading.

SKYE has a beta of 5.87, meaning it tends to be more sensitive to market movements. SKYE has a correlation of 0.25 to the broad based SPY ETF.

SKYE has a market cap of $25.63 million. This is considered a Sub-Micro Cap stock.

The top ETF exchange traded funds that SKYE belongs to (by Net Assets): VTI, VXF, IWC.

SKYE has underperformed the market in the last year with a price return of -66.4% while the SPY ETF gained +26.2%. SKYE has also underperformed the stock market ETF in the last 3 month and 2 week periods returning +3.2% and -5.9%, respectively, while the SPY returned +13.6% and -0.2%, respectively.

SKYE support price is $.74 and resistance is $.83 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SKYE shares will trade within this expected range on the day.